Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model

Table 1 Forward and reverse sequences of RT-qPCR primers

Primers
Gene	5’- 3’	3’-5’
Renin	ACCTTGCTTGTGGGATTCAC	CCTGATCCGTAGTGGATGGT
ACE1	GTGGCTGGAAGAGCAGAATC	GCCTTGGCTTCATCAGTCTC
ACE2	CAACAGAAGCCAGACAACA	GCCTTGGCTTCATCAGTCTC
AT1r	CCCTGGCTGACTTATGCTTT	ACATAGGTGATTGCCGAAGG
AT2r	GAAGCTCCGCAGTGTGTTTA	TGGCTAGGCTGATTACATGC
rMAS	TTCTCCACCATCAACAGCAG	CCTGGGTTGCATTTCATCTT
B-actin	TGTTACCAACTGGGACGACA	GGGGTGTTGAAGGTCTCAAA

ACE1: Angiotensin-converting enzyme; ACE2: Angiotensin-converting enzyme 2; AT1r: Angiotensin type-1 receptor; AT2r: Angiotensin type-2 receptor; rMAS: MAS receptor.

Table 2 Food behavior, carbohydrate metabolism and hepatic parameters

Data	C	HF	HFL	HFT
Food behavior
Energy intake (kJ/ mouse)	36.8 ± 0.8	53.3 ± 4.7a	53.4 ± 3.5a	41.9 ± 4.3c,e
Carbohydrate metabolism
Fasting glycemia (mg/dL)	120.4 ± 3.9	152.4 ± 8.5a	151.8 ± 6.3a	139.4 ± 6.8a,c,e
I/G	0.16 ± 0.03	0.27 ± 0.02a	0.19 ± 0.01c	0.18 ± 0.01c
Hepatic parameters
Hepatic Cholesterol (mg/g liver)	8.8 ± 0.2	9.6 ± 0.1a	9.5 ± 0.1a	9.3 ± 0.1a,c
Hepatic Triglycerides (mg/g liver)	10.4 ± 4.1	23.6 ± 4.7a	17.1 ± 3.9a,c	12.9 ± 2.2c
ALT (IU/L)	18.3 ± 2.8	28.6 ± 3.1a	22.8 ± 3.2a,c	22.5 ± 2.0ac

Data are expressed as the mean ± SD, (n = 5). P < 0.05 compared with the C group (a), HF group (c) and HFL group (e) (one-way ANOVA and post-hoc Holm-Sidak test). C: Control group; HF: High-fat diet; HFL: HF diet treated with losartan; HFT: HF diet treated with telmisartan; I/G: Insulin/glucose ratio; ALT: Alanine aminotransferase.